Prevalence and Associated Factors of Menstrual Irregularities Among Reproductive-age Women Attending Kaah Hospital, Hargeisa, Somaliland: A Cross-sectional Study

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background: Menstrual irregularities defines as cycles shorter than 21 days, longer than 35 days, or varying more than 7 days, impacting 5-30% of reproductive-age women globally. In Somaliland, sociocultural taboos, restricted access to sanitary products, and inadequate health infrastructure worsen underreporting and unmet needs. This study determined prevalence and the characteristics of irregular menstruation among reproductive women who visit KAAH Hospital, Hargeisa. Methods: A cross-sectional hospital-based study design enrolled 288 women aged 15-49 years from March-May 2025, via convenience sampling. A standardized questionnaire captured sociodemographic, menstrual history, lifestyle, psychosocial measures (Perceived Stress Scale, Generalized Anxiety Disorder-7), and medical history (PCOS, thyroid). Hormonal assays (prolactin, TSH, LH, and FSH) were examined for possible instances. Bivariate analysis (chi-square tests) identified variables associated with irregular menstruation at a significance level of p < 0.05. Results: The frequency of irregular menstruation was 85.76%. Age (peak 25–29 years; p <0.001), income <$100 ( p <0.001), hormonal imbalances (e.g., 24.61% low LH; p <0.001), stress ( p =0.039), anxiety ( p =0.018), an unhealthy diet (66.26%; p <0.001), and less than seven hours of sleep per night (71.95%; p <0.001). Low gonadotropins and thyroid problems (18.46% elevated TSH) suggested ovarian disturbances, maybe subclinical PCOS. Conclusion: In Somaliland, high incidence indicates the need for urgent integrated screening for hormonal, psychosocial, and lifestyle risks. Education, nutrition, and FGM/C mitigation are SDG 3/5-aligned treatments that could promote reproductive equity by preventing infertility, metabolic risks, and inequities.

Article activity feed